419 related articles for article (PubMed ID: 23062122)
1. Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
Saad CG; Ribeiro AC; Moraes JC; Takayama L; Goncalves CR; Rodrigues MB; de Oliveira RM; Silva CA; Bonfa E; Pereira RM
Arthritis Res Ther; 2012 Oct; 14(5):R216. PubMed ID: 23062122
[TBL] [Abstract][Full Text] [Related]
2. [Correlation between sclerostin level and radiographic changes in patients with ankylosing spondylitis].
Xie J; Yu X
Zhonghua Yi Xue Za Zhi; 2015 May; 95(17):1300-4. PubMed ID: 26081658
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.
Taylan A; Sari I; Akinci B; Bilge S; Kozaci D; Akar S; Colak A; Yalcin H; Gunay N; Akkoc N
BMC Musculoskelet Disord; 2012 Oct; 13():191. PubMed ID: 23025387
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis.
Klingberg E; Nurkkala M; Carlsten H; Forsblad-d'Elia H
J Rheumatol; 2014 Jul; 41(7):1349-56. PubMed ID: 24931960
[TBL] [Abstract][Full Text] [Related]
5. Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study.
Perrotta FM; Ceccarelli F; Barbati C; Colasanti T; De Socio A; Scriffignano S; Alessandri C; Lubrano E
J Immunol Res; 2018; 2018():9101964. PubMed ID: 29854850
[TBL] [Abstract][Full Text] [Related]
6. Effect of tumour necrosis factor-α inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity.
Korkosz M; Gąsowski J; Leszczyński P; Pawlak-Buś K; Jeka S; Siedlar M; Grodzicki T
Scand J Rheumatol; 2014; 43(1):43-8. PubMed ID: 24447112
[TBL] [Abstract][Full Text] [Related]
7. Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years.
Poddubnyy D; Fedorova A; Listing J; Haibel H; Baraliakos X; Braun J; Sieper J
J Rheumatol; 2016 Dec; 43(12):2142-2148. PubMed ID: 27803139
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of Dkk-1, sclerostin and VEGF in patients with ankylosing spondylitis and their association with smoking, and clinical, inflammatory and radiographic parameters.
Sakellariou GT; Iliopoulos A; Konsta M; Kenanidis E; Potoupnis M; Tsiridis E; Gavana E; Sayegh FE
Joint Bone Spine; 2017 May; 84(3):309-315. PubMed ID: 27369645
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis.
Sun W; Tian L; Jiang L; Zhang S; Zhou M; Zhu J; Xue J
Clin Rheumatol; 2019 Apr; 38(4):989-995. PubMed ID: 30443790
[TBL] [Abstract][Full Text] [Related]
10. Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation.
Sakellariou GT; Anastasilakis AD; Bisbinas I; Oikonomou D; Gerou S; Polyzos SA; Sayegh FE
Rheumatology (Oxford); 2015 May; 54(5):908-14. PubMed ID: 25349442
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
[TBL] [Abstract][Full Text] [Related]
12. Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis.
Gulyás K; Horváth Á; Végh E; Pusztai A; Szentpétery Á; Pethö Z; Váncsa A; Bodnár N; Csomor P; Hamar A; Bodoki L; Bhattoa HP; Juhász B; Nagy Z; Hodosi K; Karosi T; FitzGerald O; Szücs G; Szekanecz Z; Szamosi S; Szántó S
Clin Rheumatol; 2020 Jan; 39(1):167-175. PubMed ID: 31522318
[TBL] [Abstract][Full Text] [Related]
13. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study.
Inman RD; Baraliakos X; Hermann KA; Braun J; Deodhar A; van der Heijde D; Xu S; Hsu B
Arthritis Res Ther; 2016 Dec; 18(1):304. PubMed ID: 28031053
[TBL] [Abstract][Full Text] [Related]
14. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.
Lord PA; Farragher TM; Lunt M; Watson KD; Symmons DP; Hyrich KL;
Rheumatology (Oxford); 2010 Mar; 49(3):563-70. PubMed ID: 20032223
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of periostin and factors associated with new bone formation in ankylosing spondylitis: Periostin may be associated with the Wnt pathway.
Solmaz D; Uslu S; Kozacı D; Karaca N; Bulbul H; Tarhan EF; Ozmen M; Can G; Akar S
Int J Rheum Dis; 2018 Feb; 21(2):502-509. PubMed ID: 28941122
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin and Dkk-1 in patients with ankylosing spondylitis.
Ustun N; Tok F; Kalyoncu U; Motor S; Yuksel R; Yagiz AE; Guler H; Turhanoglu AD
Acta Reumatol Port; 2014; 39(2):146-51. PubMed ID: 25111416
[TBL] [Abstract][Full Text] [Related]
17. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
18. Association between bone turnover markers, clinical variables, spinal syndesmophytes and bone mineral density in Mexican patients with ankylosing spondylitis.
Gamez-Nava JI; de la Cerda-Trujillo LF; Vazquez-Villegas ML; Cons-Molina F; Alcaraz-Lopez MF; Zavaleta-Muñiz SA; Rocha-Muñoz AD; Martinez-Garcia EA; Corona-Sanchez EG; Salazar-Paramo M; Fajardo-Robledo NS; Olivas-Flores EM; Cardona-Muñoz EG; Gonzalez-Lopez L
Scand J Rheumatol; 2016 Nov; 45(6):480-490. PubMed ID: 27218482
[TBL] [Abstract][Full Text] [Related]
19. Assessment of serum asymmetric dimethylarginine levels and left ventricular diastolic function in patients with ankylosing spondylitis.
Inci U; Yildiz A; Batmaz I; Tekbas E
Int J Rheum Dis; 2017 Feb; 20(2):238-244. PubMed ID: 26012572
[TBL] [Abstract][Full Text] [Related]
20. Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab.
Braun J; Baraliakos X; Hermann KG; Xu S; Hsu B
J Rheumatol; 2016 Sep; 43(9):1704-12. PubMed ID: 27422890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
